Myeloproliferative Neoplasms (MPN)

Latest News

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

VTCE might be useful to identify portal hypertension beyond splenomegaly in patients with BCR::ABL1-negative MPN. | Image credit:| Dr_Microbe - stock.adobe.com
Spleen Stiffness Measurement Linked With Portal Hypertension in MPNs

June 7th 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

June 3rd 2025

The findings highlight the limitations of existing risk-stratification algorithms as they apply to adolescents and young adults with ET and PV. | Image credit: Eleni - stock.adobe.com
Interferon Cuts Risk of MF—but Not Thrombosis—in Young Patients With MPNs

May 28th 2025

The findings also show that ropeginterferon alfa-2b is an effective therapy for molecular response in early polycythemia vera. | Image credit: fotogurmespb.- stock.adobe.com
Molecular Response to Therapy Linked With Event-Free Survival in PV

May 23rd 2025

AJMC Provides Myelofibrosis Guideline Updates

Watch the series now!

AJMC Provides Myelofibrosis Guideline Updates
<123

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo